200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Appoints John C. Reed, M.D., Ph.D., to its Board of Directors
Financial Results, Press Release
Stockholders Approve Madrigal Pharmaceuticals 2026 Stock Plan
Reports First-Quarter 2026 Financial Results and Provides Corporate Updates
Board Reclassification of Directors at Madrigal Pharmaceuticals
Annual Report to Security Holders
Reports Fourth-Quarter and Full-Year 2025 Financial Results
First Amendment to Research Agreement with Roche Signed by Madrigal
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Amended Schedule 13G - Ownership Report
Submission Upload
Correspondence